Our research focuses on precision imaging and targeted immunotherapy of diseases in which dysregulated inflammation plays a detrimental role, such as cancer and atherosclerosis.


We integrate chemistry, library technology, bioengineering, immunology, advanced noninvasive imaging methods, and animal models to best design –and interactively fine tune– nanotechnology-based immunotherapies. Such nanoimmunotherapies can be applied to empower the immune system’s ability to fight disease, by promoting or inhibiting an immune response, by polarizing macrophage function, or by targeting myeloid cell dynamics. In a sequence of comprehensive mouse studies, we have shown this strategy’s ability to resolve inflammatory atherosclerosis, which we fine-tuned using in vivo library screening procedures.


To facilitate translation, we develop sophisticated in vivo imaging methods to measure immunological processes non-invasively. This enables the longitudinal evaluation of our nanoimmunotherapies in animal models of cardiovascular diseases, allograft transplantation and cancer. For example, we develop positron emission tomography (PET) tracers to study myeloid cell dynamics in cancer models, as well as in different atherosclerosis models, including mice, rabbits and swine.


Our goal is translating our immunotherapies and immuno-imaging approaches to the clinic and improve the lives of patients.